Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of zanubrutinib + rituximab versus bendamustine + rituximab in untreated transplant-ineligible mantle cell lymphoma
CTR20201544Phase 3Active
- Sponsor
- BeOne Medicines
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zanubrutinib, rituximab, bendamustine in mantle cell lymphoma (MCL), sponsored by BeOne Medicines. Started Aug 2020; status: active.
02
Drugs
zanubrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20201544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201544.